drugset
drugset / Trial / NCT00061529

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00061529 ↗

Phase 3 Completed Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2003-01
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.15 % Other

Indications

ocular hypertension open-angle glaucoma